An investigation on behalf of investors in Immunomedics, Inc. (NASDAQ:IMMU) shares over potential wrongdoing at Immunomedics was announced and NASDAQ:IMMU stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 12/19/2017 -- An investigation was announced for investors in shares of Immunomedics, Inc. (NASDAQ:IMMU) was announced over potential breaches of fiduciary duties by certain officers and directors at Immunomedics.
Investors who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU) and currently hold any of those NASDAQ:IMMU shares have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Immunomedics directors breached their fiduciary duties and caused damage to the company and its shareholders.
Morris Plains, NJ based Immunomedics, Inc. is a clinical-stage biopharmaceutical company. Immunomedics, Inc. reported that Total Revenue declined from $3.23 million for the 12 months period that ended on June 30, 2016 to $3.09 million for the 12 months period that ended on June 30, 2017 and that its Net Loss increased over those time periods from $59.04 million to $153.21 million.
Shares of Immunomedics, Inc. (NASDAQ:IMMU) closed on December 18, 2017 at $12.69 per share.
Those who purchased shares of Immunomedics, Inc. (NASDAQ:IMMU), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels